Camarda Financial Advisors’s Novo Nordisk NVO Stock Holding History

Camarda Financial Advisors’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-11,826	Closed	-$1.69M	–	89
2024 Q2	$1.69M	Buy	+11,826	New	+$1.57M	0.66%	52
2024 Q1	–	Sell	-1,976	Closed	-$204K	–	82
2023 Q4	$204K	Buy	+1,976	New	+$195K	0.09%	78
2022 Q4	–	Sell	-6,336	Closed	-$316K	–	86
2022 Q3	$316K	Buy	+6,336	New	+$339K	0.37%	52
2019 Q3	–	Sell	-1,190	Closed	-$30K	–	333
2019 Q2	$30K	Buy	1,190 +132	+12%	+$3.26K	0.06%	105
2019 Q1	$28K	Buy	+1,058	New	+$26K	0.05%	110
2016 Q4	–	Sell	-550	Closed	-$11K	–	276
2016 Q3	$11K	Hold	550	–	–	0.01%	172
2016 Q2	$15K	Buy	+550	New	+$15.1K	0.01%	194
2013 Q3	–	Sell	-290	Closed	-$4K	–	185
2013 Q2	$4K	Buy	+290	New	+$4.83K	﹤0.01%	218

Other funds holding NVO

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Fayez Sarofim & Co Houston, Texas $42.5B AUM 18.19% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Camarda Financial Advisors's NVO Position: Q3 2024 in Review

Camarda Financial Advisors sold out of Novo Nordisk (NVO) in Q3 2024, closing a stake of 11,826 shares — an estimated $1.69M sold.

Camarda Financial Advisors first reported a position in NVO in Q2 2013 and held it in 8 quarters. The position peaked at $1.69M in Q2 2024. 1,786 funds tracked by Wall St. Rank hold NVO as of Q3 2024.

Camarda Financial Advisors reported no remaining Novo Nordisk position as of Q3 2024 after selling out during the quarter.
Camarda Financial Advisors sold 11,826 Novo Nordisk shares in Q3 2024, an estimated $1.69M.
Camarda Financial Advisors first reported a position in Novo Nordisk in Q2 2013 and held it in 8 quarters.
Camarda Financial Advisors's Novo Nordisk position peaked at $1.69M in Q2 2024.
1,786 funds tracked by Wall St. Rank held Novo Nordisk as of Q3 2024.

Based on Camarda Financial Advisors's 13F filing for Q3 2024, filed 12 Nov 2024.